Dr Gabe Musso, Chief Scientific Officer, Lunai Bioworks, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026.

He will present: De-Risking the Translation Gap: Coupling AI with High-Throughput In Vivo Models.

You can register your interest here.

For the third year running DDW is organising this series of seminars at SLAS International Conference and Exhibition. Based on the SLAS2026 theme of Catalyze Discovery, these will be available to visitors of SLAS2026 (7-11 February 2026, Boston, USA).

This programme, Creating Cures: The role of lab automation in successful drug discovery at SLAS2026 – will highlight innovative research using technology in drug development and will be held in the Ignite Theater on 9 and 10 February

Dr Musso has a background in molecular genetics (PhD), and did post-doctoral work at Harvard Medical School and Brigham and Women’s Hospital on computational and developmental biology. He spent time at a start-up working on real-time machine learning, before joining with others to start BioSymetrics with the aim of tackling the specific challenges of working with biomedical data. He was named one of the top 100 leaders in AI and drug discovery, has authored over 30 peer reviewed publications on AIML and biology.

The track is sponsored by Collaborative Drug Discovery (CDD), Brooks Automation and Thermo Fisher Scientific.

Let us know if you’re attending by registering your interest.